More particularly the book contains an analysis of lower VP-adverbs in Kavalan as serial verbs (Chang), a defense of two types of adverbial heads in Seediq (Holmer), an account of possible DP-internal serializations in Niuean in terms of remnant movement (Kahnemuyipour Massam), a plea for relative, scope-based adverb ordering in Tagalog (Kaufman), a clefting approach to unbounded dependencies in Malagasy (Potsdam), a critical assessment of constraints on remnant movement as applied to adverb orderings in Malagasy (Thiersch), and an analysis of the Malagasy voice system on the basis of clitic left-dislocation (Travis). The editors' introduction undertakes a critical survey of the relevant empirical and theoretical background.
A substantial part of the empirical facts are presented here for the first time, and the book will inspire additional systematic investigation of the often neglected aspects of modificational strategies in Austronesian languages.
The book will be of value to linguists interested in contemporary syntactic analysis and to everyone seeking a deeper understanding of the formal properties of Austronesian.
“This book is a necessity for understanding the pharmaceutical industry. Both the pluses and minuses of the present system are set forth with a judicious combination of historical narrative, economic analysis, and statistical data. The highly original proposals for reform will be a major stimulant to analysis and policy-making.”
–Kenneth Arrow, Nobel Laureate in Economics, Professor Emeritus, Stanford University
“This is a timely book by authors who know what they are talking about. They tackle a big problem: rising drug prices that are threatening to overwhelm us all–and especially those with limited or absent health care insurance. Will we drive people overseas for healthcare? Will there be social unrest? This book describes the problem and then offers a solution. Worth a careful read by everyone, pharmaceutical manufacturers and government policymakers especially.”
–Roger Williams, M.D., Chief Executive Officer of the United States Pharmacopeia and a former
senior official of the Food and Drug Administration
“This book confounds two sets of skeptics: Those who say there’s no way to resolve the conflict between the need to fund pharmaceutical research and our desire to keep medicine affordable; and those who think that economics never has anything good to say.”
–Honorable Barney Frank, Congressman from Massachusetts
“This book comes at the right time and could become the starting point of discussions, which will eventually lead us into new era in the healthcare care industry. It will without a doubt become a must for insiders of the pharma- and biotech industries.”
–Dr. Jürgen Drews, retired President of Roche Pharmaceutical Group Global Research
About the Authors ix
Chapter 1: Drugs and Drug Prices 1
Chapter 2: The American Way to Discover Drugs 21
Chapter 3: The Drug Industry Today 39
Chapter 4: Are Drug Companies Risky? 59
Chapter 5: How Not to Lower Drug Prices 77
Chapter 6: Squandering R & D Resources 103
Chapter 7: How to Lower Drug Prices 129
Appendix: Our Solution in Detail 155
Editors Martin and Bial have brought together a unique compendium which covers all the key areas including:
* the development of Brecht's aesthetic theories
* the relationship of Epic theatre to orthodox dramatic theatre
* Brecht's collaboration with Kurt Weill, Paul Dessau and Max Frisch
* Brecht's influence on a variety of cultures and contexts including England, Italy , Moscow and Japan.
Together these essays are an ideal companion to Brecht's plays, and provide an invaluable reconsideration of Brecht's work.
Contributors include: Werner Hecht, Mordecai Gorelik, Eric Bentley, Jean-Paul Sartre, Kurt Weill, Ernst Bloch, Darko Suvin, Carl Weber, Paul Dessau, Denis Calandra, W. Stuart McDowell, Ernst Schmacher, Hans-Joachim Bunge, Martin Esslin, Artuto Lazzari, Tadashi Uchino, Diana Taylor, Elin Diamond, and Lee Baxandall.